[{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Karyopharm Therapeutics | AbbVie Inc | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ Karyopharm Therapeutics | AbbVie Inc | Gateway for Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ Karyopharm Therapeutics | AbbVie Inc | Gateway for Cancer Research"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Johnson & Johnson Innovative Medicine | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Johnson & Johnson Innovative Medicine | Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Hackensack Meridian Health \/ Johnson & Johnson Innovative Medicine | Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ AbbVie Inc"},{"orgOrder":0,"company":"The First Affiliated Hospital of Xiamen University","sponsor":"Huizhou Municipal Central Hospital | Shenzhen Chipscreen Biosciences | CSPC Pharmaceutical Group | Fujian Provincial Hospital | Fujian Cancer Hospital | Zhangzhou Municipal Hospital, Fujian Province | Jieyang People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"The First Affiliated Hospital of Xiamen University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital of Xiamen University \/ Huizhou Municipal Central Hospital | Shenzhen Chipscreen Biosciences | CSPC Pharmaceutical Group | Fujian Provincial Hospital | Fujian Cancer Hospital | Zhangzhou Municipal Hospital, Fujian Province | Jieyang People's Hospital","highestDevelopmentStatusID":"8","companyTruncated":"The First Affiliated Hospital of Xiamen University \/ Huizhou Municipal Central Hospital | Shenzhen Chipscreen Biosciences | CSPC Pharmaceutical Group | Fujian Provincial Hospital | Fujian Cancer Hospital | Zhangzhou Municipal Hospital, Fujian Province | Jieyang People's Hospital"},{"orgOrder":0,"company":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nordic Lymphoma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Lymphoma Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Lymphoma Group \/ Undisclosed"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc"},{"orgOrder":0,"company":"French Innovative Leukemia Organisation","sponsor":"AbbVie Inc | Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"French Innovative Leukemia Organisation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"French Innovative Leukemia Organisation \/ AbbVie Inc | Janssen-Cilag","highestDevelopmentStatusID":"8","companyTruncated":"French Innovative Leukemia Organisation \/ AbbVie Inc | Janssen-Cilag"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc"},{"orgOrder":0,"company":"French Innovative Leukemia Organisation","sponsor":"Stemline Therapeutics | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"French Innovative Leukemia Organisation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"French Innovative Leukemia Organisation \/ Stemline Therapeutics | AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"French Innovative Leukemia Organisation \/ Stemline Therapeutics | AbbVie Inc"},{"orgOrder":0,"company":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori","sponsor":"Hospital Vall d'Hebron | Cyprus Institute of Neurology and Genetics | European Leukemia Net | Fundacion Para La Investigacion Hospital La Fe | Ostdeutsche Studiengruppe Haematologie und Onkologie | Ospedale Pediatrico Bambino Gesu | Czech Lymphoma Study G","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori \/ Hospital Vall d'Hebron | Cyprus Institute of Neurology and Genetics | European Leukemia Net | Fundacion Para La Investigacion Hospital La Fe | Ostdeutsche Studiengruppe Haematologie und Onkologie | Ospedale Pediatrico Bambino Gesu | Czech Lymphoma Study G","highestDevelopmentStatusID":"10","companyTruncated":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori \/ Hospital Vall d'Hebron | Cyprus Institute of Neurology and Genetics | European Leukemia Net | Fundacion Para La Investigacion Hospital La Fe | Ostdeutsche Studiengruppe Haematologie und Onkologie | Ospedale Pediatrico Bambino Gesu | Czech Lymphoma Study G"},{"orgOrder":0,"company":"Fondazione Italiana Linfomi","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Fondazione Italiana Linfomi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Italiana Linfomi \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Fondazione Italiana Linfomi \/ AbbVie Inc"},{"orgOrder":0,"company":"Stichting Hemato-Oncologie voor Volwassenen Nederland","sponsor":"German-Austrian Acute Myeloid Leukemia Study Group | United Kingdom AML Research Network | Gruppo Italiano Malattie EMatologiche dell'Adulto | Swiss Group for Clinical Cancer Research | Danish Acute Leukemia Group | Grupo Cooperativo de Estudio y Tratamie","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Stichting Hemato-Oncologie voor Volwassenen Nederland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stichting Hemato-Oncologie voor Volwassenen Nederland \/ German-Austrian Acute Myeloid Leukemia Study Group | United Kingdom AML Research Network | Gruppo Italiano Malattie EMatologiche dell'Adulto | Swiss Group for Clinical Cancer Research | Danish Acute Leukemia Group | Grupo Cooperativo de Estudio y Tratamie","highestDevelopmentStatusID":"10","companyTruncated":"Stichting Hemato-Oncologie voor Volwassenen Nederland \/ German-Austrian Acute Myeloid Leukemia Study Group | United Kingdom AML Research Network | Gruppo Italiano Malattie EMatologiche dell'Adulto | Swiss Group for Clinical Cancer Research | Danish Acute Leukemia Group | Grupo Cooperativo de Estudio y Tratamie"},{"orgOrder":0,"company":"Technische Universit\u00e4t Dresden","sponsor":"University Hospital Heidelberg | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Technische Universit\u00e4t Dresden","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Technische Universit\u00e4t Dresden \/ University Hospital Heidelberg | AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Technische Universit\u00e4t Dresden \/ University Hospital Heidelberg | AbbVie Inc"},{"orgOrder":0,"company":"Technische Universit\u00e4t Dresden","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Technische Universit\u00e4t Dresden","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Technische Universit\u00e4t Dresden \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Technische Universit\u00e4t Dresden \/ AbbVie Inc"},{"orgOrder":0,"company":"University of Leipzig","sponsor":"AbbVie Inc | University Hospital Leipzig (Hematology Diagnostics Lab) | University of Leipzig Clinical Trial Centre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"University of Leipzig","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leipzig \/ AbbVie Inc | University Hospital Leipzig (Hematology Diagnostics Lab) | University of Leipzig Clinical Trial Centre","highestDevelopmentStatusID":"8","companyTruncated":"University of Leipzig \/ AbbVie Inc | University Hospital Leipzig (Hematology Diagnostics Lab) | University of Leipzig Clinical Trial Centre"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ AbbVie Inc"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc | German CLL Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie Inc | German CLL Study Group","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ AbbVie Inc | German CLL Study Group"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ AbbVie Inc"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ AbbVie Inc"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ AbbVie Inc"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"University of Colorado, Denver \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Hackensack Meridian Health","highestDevelopmentStatusID":"8","companyTruncated":"Georgetown University \/ Hackensack Meridian Health"},{"orgOrder":0,"company":"Canadian Cancer Trials Group","sponsor":"F. Hoffmann-La Roche | AbbVie Inc | Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Canadian Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Cancer Trials Group \/ F. Hoffmann-La Roche | AbbVie Inc | Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Canadian Cancer Trials Group \/ F. Hoffmann-La Roche | AbbVie Inc | Incyte Corporation"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ AbbVie Inc"},{"orgOrder":0,"company":"PrECOG","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"PrECOG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrECOG \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PrECOG \/ Genentech"},{"orgOrder":0,"company":"PrECOG","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"PrECOG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrECOG \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"PrECOG \/ Genentech"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Michigan Rogel Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Genentech | Massachusetts General Hospital | MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Genentech | Massachusetts General Hospital | MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Weill Medical College of Cornell University \/ Genentech | Massachusetts General Hospital | MD Anderson Cancer Center"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Genentech | Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Genentech | Epizyme","highestDevelopmentStatusID":"6","companyTruncated":"Weill Medical College of Cornell University \/ Genentech | Epizyme"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Syndax Pharmaceuticals | Break Through Cancer | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Syndax Pharmaceuticals | Break Through Cancer | AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Syndax Pharmaceuticals | Break Through Cancer | AbbVie Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Kura Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Kura Oncology","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Kura Oncology"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Virginia Commonwealth University \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech | Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Genentech | Celgene Corporation"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"General Hospital of Chinese Armed Police Forces","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ General Hospital of Chinese Armed Police Forces","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ General Hospital of Chinese Armed Police Forces"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Sumitomo Pharma America","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Sumitomo Pharma America"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Merck & Co"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Astellas Pharma | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Astellas Pharma | Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Astellas Pharma | Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech | Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech | Amgen Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Immunology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Bristol Myers Squibb | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Bristol Myers Squibb | Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Bristol Myers Squibb | Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Nephrology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca | Genentech | National Institutes of Health | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca | Genentech | National Institutes of Health | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca | Genentech | National Institutes of Health | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ BeOne Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ BeOne Medicines"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Adaptive Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Adaptive Biotechnologies","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Adaptive Biotechnologies"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONCOtherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONCOtherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"James P. Wilmot Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG Therapeutics \/ James P. Wilmot Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"TG Therapeutics \/ James P. Wilmot Cancer Center"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc | Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc | Genentech"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Melbourne Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Melbourne Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melbourne Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melbourne Health \/ Undisclosed"},{"orgOrder":0,"company":"Qurient","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Adrixetinib","moa":"||AXL\/Mer\/CSF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qurient \/ Undisclosed"},{"orgOrder":0,"company":"University of New Hampshire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"JQ-1","moa":"||BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of New Hampshire","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Hampshire \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of New Hampshire \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||BTN3A\/gamma-9-delta-2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImCheck Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Midcap Financial Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Midcap Financial Trust","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Midcap Financial Trust"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Eckert & Ziegler Strahlen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Eckert & Ziegler Strahlen","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Eckert & Ziegler Strahlen"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shattuck Labs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shattuck Labs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Undisclosed"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Undisclosed"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series A Financing","leadProduct":"Cusatuzumab","moa":"||CD70 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"OncoVerity \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity \/ Argenx"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"||CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RVU120","moa":"||CDK8","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enitociclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vincerx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tambiciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tambiciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||Cellular tumor antigen p53","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||Cellular tumor antigen p53","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEI Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEI Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Decitabine","moa":"||DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astex Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Astex Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Daunorubicin","moa":"||DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"HiberCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Undisclosed"},{"orgOrder":0,"company":"HiberCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||Growth factor receptor-bound protein 2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||Growth factor receptor-bound protein 2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||Growth factor receptor-bound protein 2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||Growth factor receptor-bound protein 2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||Growth factor receptor-bound protein 2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Financing","leadProduct":"Azacitidine","moa":"||IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Termination","leadProduct":"Azacitidine","moa":"||IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":1.46,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.46,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||IL3RA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase II","graph3":"Oncternal Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Oncternal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Curis","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Curis \/ Laidlaw & Company","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Laidlaw & Company"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Celgene Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ AbbVie Inc"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte immunoglobulin-like receptor B4 (LILRB4)","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immune-Onc Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Pharmacyclics"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"||Lysine-specific histone demethylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imago BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KT-253","moa":"||MDM2","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||MEN1","graph1":"Oncology","graph2":"Phase III","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kura Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Termination","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":1.9399999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.9399999999999999,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Devimistat","moa":"||PDK","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"||RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||Selectin E","graph1":"Oncology","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crescent Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TG Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Loxo-305","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loxo Oncology Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncology Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"||Tyrosine-protein kinase receptor UFO | Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lin BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Granaticin B","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lin BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lin BioScience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lin BioScience \/ Undisclosed"},{"orgOrder":0,"company":"Mendus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"5-Azacytidine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Craig Portell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Craig Portell","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Craig Portell"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Gottfried von Keudell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Gottfried von Keudell","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Gottfried von Keudell"},{"orgOrder":0,"company":"Genentech","sponsor":"Rajshekhar Chakraborty, MD","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Rajshekhar Chakraborty, MD","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Rajshekhar Chakraborty, MD"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Andrew E. Place","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Andrew E. Place","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Andrew E. Place"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Ioannis Mantzaris","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Ioannis Mantzaris","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Ioannis Mantzaris"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Thomas Ernst, PD Dr. med.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Thomas Ernst, PD Dr. med.","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Thomas Ernst, PD Dr. med."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Alfred Chung","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Alfred Chung","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Alfred Chung"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Antonio M Jimenez Jimenez","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Antonio M Jimenez Jimenez","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Antonio M Jimenez Jimenez"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Christian Buske","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Christian Buske","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Christian Buske"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Sanjay Mohan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Oncology \/ Sanjay Mohan","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Oncology \/ Sanjay Mohan"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Michael Choi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Michael Choi","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Michael Choi"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Sanjay Mohan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karyopharm Therapeutics \/ Sanjay Mohan","highestDevelopmentStatusID":"6","companyTruncated":"Karyopharm Therapeutics \/ Sanjay Mohan"}]
Find Clinical Drug Pipeline Developments & Deals for Venetoclax
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
